HONY MEDIA-NEW(00419): Selling all shares of Heartily Health Limited.
The Hongyi Cultural Group (00419) announced that on January 30, 2026, the seller (Meerkat Health Holdings Limited, wholly owned by the company) and the buyer, Mr. Xu Chun Sheng, entered into a purchase agreement. According to this agreement, the seller has agreed to sell and the buyer has agreed to purchase all the issued shares of the target company, Heartily Health Limited; and the seller has agreed to transfer to the buyer, and the buyer has agreed to assume shareholder loans, for a total consideration of 1 Hong Kong dollar.
HONY MEDIA-NEW (00419) announcement, as of January 30, 2026, the seller (Meerkat Health Holdings Limited, fully owned by the company) and the buyer Mr. XU Chun Sheng entered into a sales agreement. Accordingly, the seller has agreed to sell and the buyer has agreed to acquire all the issued shares of the target company Heartily Health Limited; and the seller has agreed to transfer to the buyer, and the buyer has agreed to assume shareholder loans, for a total consideration of 1 Hong Kong dollar.
Upon completion, the company will sell all its equity interests in the target company, therefore the target company will no longer be a subsidiary of the group. The financial performance, assets, and liabilities of the sold group will no longer be consolidated into the group's consolidated financial statements. The completion has been implemented as of January 30, 2026.
The target company is a limited company registered in Hong Kong, mainly engaged in investment holding. Prior to the sale, the target company was fully owned by the seller. The target company, together with its subsidiaries (i.e. the sold group), is mainly engaged in the operation of a medical e-commerce internet platform and smart healthcare and medical services business. The business of the sold group is classified as one of the operating divisions of the group, namely the "smart healthcare service platform."
The sale allows the group to optimize its asset allocation and focus on areas and businesses with stronger growth potential. This also enables the group to reallocate internal resources by eliminating loss-making businesses to support its existing core businesses in entertainment and media; and the development of digital operational services in the medical industry, thereby enhancing the group's overall financial flexibility.
Related Articles

New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?
New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?

RECOMMEND

Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
30/01/2026

Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
30/01/2026

2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
30/01/2026


